All content on this page is for research and educational purposes only. Ipamorelin is a research compound supplied for laboratory use. It is not approved for human therapeutic use in the UK and is not intended to diagnose, treat, cure or prevent any condition.
Introduction: GH Axis Interactions with Reproductive Endocrinology
The growth hormone/IGF-1 axis and the hypothalamic-pituitary-gonadal (HPG) axis are not independent systems — they interact at multiple levels, and dysregulation of one has demonstrable consequences for the other. The clinical implications of this interaction are recognised in practice: children with GH deficiency experience delayed puberty, GH-deficient adults show impaired gonadal function, and conditions that suppress the GH axis (caloric restriction, overtraining syndrome, chronic illness) frequently produce concurrent reproductive hormone dysregulation.
Ipamorelin is a synthetic pentapeptide GH secretagogue with selective GHS-R1a agonist activity — it stimulates pulsatile GH release without significant effects on cortisol, ACTH, or prolactin at research-relevant doses. This selectivity makes ipamorelin particularly valuable for research examining the isolated GH axis contribution to reproductive hormone biology, without the confounding effects of stress hormone co-elevation that complicate research with less selective secretagogues such as GHRP-6 or hexarelin.
GH/IGF-1 Effects on Gonadal Function: The Mechanistic Landscape
The GH/IGF-1 axis influences gonadal function through multiple converging mechanisms spanning the hypothalamus, pituitary, and gonads directly:
Hypothalamic and Pituitary Level
GH receptors (GHR) are expressed in hypothalamic nuclei relevant to GnRH neuron regulation — including the arcuate nucleus where KNDy neurons reside. Research has demonstrated that IGF-1 (produced in the liver under GH stimulation) directly acts on GnRH neurons, which express IGF-1R, to modulate GnRH pulse frequency and amplitude. IGF-1 signalling on GnRH neurons activates PI3K/Akt pathways that increase GnRH neuronal excitability and promote GnRH release.
IGF-1 also acts at the pituitary level — on gonadotroph cells expressing IGF-1R — to enhance LH and FSH secretion in response to GnRH stimulation. Research has shown that IGF-1 increases the amplitude of LH pulses released per GnRH stimulus, effectively amplifying gonadotrophin output without increasing GnRH pulse frequency. This amplification is physiologically relevant: in states of GH/IGF-1 deficiency, reduced gonadotrophin amplification impairs LH surge formation and ovarian function in females, and impairs Leydig cell stimulation in males.
Ovarian Level: IGF-1R Signalling in Granulosa and Theca Cells
The ovary is a major IGF-1 target organ. IGF-1R is highly expressed on granulosa cells — the somatic cells surrounding each oocyte within developing follicles — and on theca cells (the androgen-producing cells of the follicle wall). IGF-1 signalling in granulosa cells serves several critical functions in folliculogenesis:
IGF-1 amplifies FSH signalling in granulosa cells — increasing FSH receptor expression, sensitising adenylyl cyclase coupling, and amplifying downstream cAMP production. In practical terms, this means that in the presence of adequate IGF-1, lower FSH concentrations are required to drive follicular growth — and IGF-1 deficiency means that the same FSH concentration produces a suboptimal follicular response. This mechanism is why women with GH deficiency or severe GH receptor insensitivity (Laron syndrome) frequently show poor ovarian response to controlled ovarian stimulation.
IGF-1 promotes granulosa cell proliferation (via MAPK/ERK), inhibits granulosa cell apoptosis (via PI3K/Akt), and stimulates aromatase (CYP19A1) expression — the enzyme converting androgens to oestrogens within the follicle. Adequate intra-follicular oestrogen production is required for continued folliculogenesis and for the positive oestrogen feedback that triggers the LH surge and ovulation.
Testicular Level: Sertoli and Leydig Cell IGF-1R Biology
In the male reproductive system, IGF-1R is expressed on both Sertoli cells (which support spermatogenesis) and Leydig cells (which produce testosterone). IGF-1 signalling in Sertoli cells supports their ability to maintain the blood-testis barrier, provide nutritional support to developing spermatocytes, and produce androgen-binding protein — all essential for normal spermatogenesis. IGF-1R signalling in Leydig cells amplifies LH-stimulated testosterone production — analogous to its FSH-amplifying role in granulosa cells. GH-deficient males consistently show reduced testosterone production and impaired spermatogenesis that partially responds to GH replacement.
Ipamorelin-Specific Research Advantages in Reproductive Contexts
Ipamorelin’s selectivity profile makes it distinctively useful for research examining the GH axis-reproductive axis interaction:
No cortisol elevation: Cortisol is catabolic to reproductive function — elevated cortisol suppresses GnRH pulse frequency, inhibits LH and FSH release at the pituitary, and directly impairs gonadal steroidogenesis. In any research examining GH axis stimulation and reproductive outcomes, cortisol co-elevation (as occurs with GHRP-6, hexarelin, and other less selective secretagogues) would be a significant confound. Ipamorelin’s documented lack of cortisol elevation at research-relevant doses allows cleaner attribution of reproductive effects to GH/IGF-1 axis stimulation.
No prolactin elevation: Hyperprolactinaemia is a well-recognised cause of reproductive dysfunction — it inhibits GnRH pulse generation, suppresses LH and FSH, and in females directly inhibits ovarian folliculogenesis and luteal function. Some GH secretagogues with ghrelin receptor activity (GHRP-2, GHRP-6) can elevate prolactin. Ipamorelin’s selective GHS-R1a agonism without prolactin elevation makes it preferable for reproductive research contexts where prolactin must be controlled.
Physiological GH pulsatility: Ipamorelin stimulates GH release in a manner that preserves physiological pulsatility — augmenting natural pulses rather than generating sustained supraphysiological GH elevation. This pulsatile pattern is more analogous to the endogenous GH secretory pattern that normally supports reproductive function, making ipamorelin-generated GH/IGF-1 elevations a more physiologically relevant research stimulus than sustained GH infusion protocols.
Research Evidence: GH Secretagogues and Reproductive Function
While direct ipamorelin-reproductive function research is limited, the broader GH secretagogue literature provides mechanistic context:
GH secretagogues and IVF outcomes: Small studies examining growth hormone co-treatment in poor ovarian responders undergoing IVF — based on the hypothesis that increasing intra-follicular IGF-1 would amplify FSH sensitivity — have shown promising signals in some populations. The mechanism is consistent with the granulosa cell IGF-1R amplification of FSH signalling described above. Ipamorelin’s selective GH-stimulating profile without hormone side effects makes it a mechanistically appropriate tool for research specifically probing the IGF-1 component of this effect.
GH axis restoration and testosterone in hypogonadal males: Research in GH-deficient males has consistently documented partial testosterone restoration with GH replacement — mediated through IGF-1’s Leydig cell sensitisation to LH stimulation. Ipamorelin research in male GH deficiency models would enable investigation of whether GH secretagogue-driven GH/IGF-1 restoration provides similar Leydig cell sensitisation to exogenous GH replacement.
Overtraining and Hypothalamic Amenorrhoea: Relevant Research Contexts
Hypothalamic amenorrhoea (HA) — the suppression of GnRH pulsatility in response to caloric restriction, excessive exercise, or psychological stress — is characterised by simultaneous suppression of both the HPG axis and the GH/IGF-1 axis. IGF-1 levels are consistently reduced in HA, reflecting the GH axis’s sensitivity to energy availability. Research using ipamorelin in HA models provides an opportunity to examine whether selective GH/IGF-1 restoration (without the energy repletion that would also restore HPG axis function) partially rescues reproductive function — helping dissect the relative contribution of the GH/IGF-1 deficit versus the direct energy deficit to HA-associated reproductive suppression.
Similarly, overtraining syndrome in male athletes — characterised by reduced LH pulse amplitude and lower testosterone alongside reduced GH pulse amplitude and IGF-1 — represents a research model where the interaction between GH axis depression and HPG axis suppression can be studied. Ipamorelin’s ability to selectively restore GH/IGF-1 without affecting HPA axis activity makes it a clean research tool for dissecting these interactions.
Research Protocol Considerations
Hormone panel selection: Research designs examining ipamorelin’s reproductive effects should include baseline and endpoint measurement of GH (timed samples or 24-hour profile), IGF-1, LH, FSH, testosterone/oestradiol, and prolactin (as a safety control confirming ipamorelin’s lack of prolactin elevation). Cortisol should also be measured as a negative control confirming selectivity.
Intra-follicular measurement: For female reproductive research in IVF contexts, intra-follicular fluid IGF-1 measurement (by ELISA on aspirated follicular fluid) provides the most direct evidence of IGF-1 effect on granulosa cell biology — correlating local IGF-1 availability with follicular maturation markers (E2 in follicular fluid, granulosa cell aromatase expression).
Animal model selection: Ovariectomised rats on FSH replacement protocols provide a clean model for granulosa cell IGF-1R sensitisation research without the hormonal variability of intact cycling females. GH-deficient rodent models (dwarf rats, GH receptor knockout mice) allow examination of GH axis restoration effects on gonadal function without confounds from endogenous GH variability.
🔗 Related Reading: For a comprehensive overview of Ipamorelin research, mechanisms, UK sourcing, and safety data, see our Ipamorelin UK Complete Research Guide 2026.
🔗 Also See: For comparison of GH secretagogues across selectivity, half-life and research applications, see our GH Secretagogue Comparison: Ipamorelin, CJC-1295, Sermorelin and GHRP-6 Research Guide UK 2026.
Summary for Researchers
Ipamorelin’s selective GH secretagogue profile — GH stimulation without cortisol, ACTH, or prolactin elevation — makes it the most appropriate GH secretagogue for research examining the isolated GH/IGF-1 axis contribution to gonadal function. The mechanistic basis for this research is well-established: IGF-1R signalling in granulosa cells amplifies FSH-driven folliculogenesis, in gonadotroph cells amplifies LH/FSH responses to GnRH, and in Leydig cells amplifies LH-driven testosterone production. Research contexts including poor ovarian response, GH-deficient male hypogonadism, hypothalamic amenorrhoea, and overtraining syndrome all provide models where ipamorelin’s selective GH axis stimulation can be deployed to probe GH/IGF-1’s contribution to reproductive biology with minimal confounding from other hormonal effects.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Ipamorelin for research and laboratory use. View UK stock →
